Study drug 2X-121 for ovarian cancer that keeps coming back
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent.
- Your cancer is epithelial ovarian, fallopian tube, or primary peritoneal cancer with mainly serous and/or endometrioid type.
- Your cancer must be “platinum-resistant” (it grew within 6 months after the last platinum chemo) or you could not receive platinum chemo.
- You have had no more than one prior treatment line in the platinum-resistant/platinum-ineligible setting (prior antibody drug therapy like Elahere does not count as a prior line).
- You have measurable tumors on CT or MRI and are well enough for treatment (ECOG 0–1) with expected survival over 16 weeks.
- You can provide a tumor tissue sample (new biopsy if needed) and have lab tests showing your blood counts and organs are working well enough for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a new capsule, XS-02, for people with advanced solid tumors, especially ovarian cancer, that have stopped responding to standard treatments. The goal is to see if XS-02 is safe and helps shrink or control the cancer.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.